对于酒精使用障碍的相位敏感的个性化药理疗
Christian P Müller1, Bernd Lenz2, Johannes Kornhuber3
1Department of Psychiatry and Psychotherapy, University Clinic, Friedrich-Alexander-University of Erlangen-Nürnberg, Schwabachanlage 6, 91054, Erlangen, Germany; Institute of Psychopharmacology, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Neuropharmacology
|October 28, 2025
概括
需要新的酒精使用障碍 (AUD) 治疗方法. 这项研究建议将药理工具箱与人工智能合的生态瞬间评估 (EMA) 工具结合起来,用于阶段敏感,个性化的AUD治疗.
科学领域:
- 神经科学是一个神经科学.
- 精神病学是一个精神病学.
- 数字健康数字健康
背景情况:
- 酒精使用障碍 (AUD) 是一种广泛的疾病,患者遭受重大痛苦.
- 目前用于AUD的药物治疗方法的有效性有限,患者遵守性差.
- 不同的神经生物学过程是AUD不同阶段的基础 (例如,寻求,消费,戒断).
研究的目的:
- 提出一种新的,相位敏感的治疗策略,以治疗酒精使用障碍.
- 将可用的药物治疗与先进的诊断技术相结合,以实现个性化的AUD管理.
- 为了利用人工智能 (AI) 实时监测和治疗指导在AUD.
主要方法:
- 开发一种治疗策略,将药理学工具箱与生态瞬间评估 (EMA) 工具相结合.
- 使用人工智能合的EMA设备,几乎实时监控单个AUD阶段.
- 根据EMA衍生的特定阶段数据定制神经药理干预措施.
主要成果:
- 拟议的战略允许精确地定位AUD的各个阶段.
- 与人工智能结合的EMA作为诊断监测,治疗指南和成功指标.
- 这种方法促进了针对AUD的个性化,相位敏感的神经药理治疗.
结论:
- 这种结合药物治疗和人工智能驱动的EMA的创新方法可能会彻底改变AUD治疗.
- 个性化,特定阶段的干预措施有望提高治疗效率和遵守性.
- 该策略在管理精神疾病方面提供了潜在的范式转变.
相关概念视频
01:24Dosage Regimen: Individualization
165
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
165
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
248
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
248
01:28Drug Therapy
239
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
239
01:26Psychosis: Goals of Pharmacotherapy
460
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
460
01:01Dosage Regimens: Partial Pharmacokinetic Parameters
147
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
147
01:29Therapeutic Drug Monitoring: Affecting Factors
196
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
196